# Pharmaceuticals
Latest news and articles about Pharmaceuticals
Total: 10 articles found
China Approves Plant-Derived Recombinant Albumin Produced from Rice
Developed by Wuhan University researchers, the bio-manufactured drug offers an alternative to plasma-derived therapies.
China Unveils 2030 Pharma Plan Targeting 3.5 Trillion Yuan Revenue
Ten ministries release a five-year blueprint aiming for 25% of global first-in-class drugs and rapid growth in innovative medicines.
China Innovative Drugmakers Turn Profitable on Licensing and Policy
Milestone licensing revenue, rising overseas co-development, and targeted procurement reforms drive a structural turnaround for domestic biopharmas.
China Opens Bidding in Seventh Bulk Procurement Round for Medical Consumables
The latest national tender targets 23 types of digestive intervention devices, drawing bids from 156 companies.
Beijing Pilot Free Trade Zone Expands Institutional Opening Reforms
Regulatory experiments in cross-border data flows, rare disease drug imports, and financial services yield models for wider rollout.
China Outlines Healthcare Security Priorities for the 15th Five-Year Plan
Authorities plan to expand coverage for gig workers, establish long-term care insurance, and broaden volume-based procurement.
China's Pharma Sector Sees Surge in Drug Approvals and Out-Licensing in H1
Domestic developers accounted for over 80% of new innovative drug approvals as overseas licensing deals hit $110 billion.
E-Commerce Platforms Emerge as Primary Debut Channels for New Drugs in China
Leading platforms hosted debuts for the vast majority of innovative medicines in 2025, bypassing lengthy hospital procurement cycles.
China Standardizes 12th Bulk Drug Procurement Batch Covering 65 Categories
China's healthcare authority includes 65 drug varieties in its latest centralized procurement round, shifting toward longer contract terms and rational pricing.
Media Report Highlights Profit Surge at Joinn Laboratories
Mainland media coverage points to a reported net profit increase of over 1,300 percent for the preclinical research organization, focusing attention on biological asset valuations.